Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Burkitt Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lung Neoplasms 4Meningeal Carcinomatosis 3Lymphoma, Large B-Cell, Diffuse 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Glioma 2Glioblastoma 2Astrocytoma 2Uveal Melanoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Oligodendroglioma 1Nevus 1Meningeal Neoplasms 1Melanoma 1Lymphoma, T-Cell 1Lymphoma, Follicular 1Leukemia, Myelomonocytic, Juvenile 1Leukemia, Monocytic, Acute 1Leukemia, Hairy Cell 1Germinoma 1Diabetes Insipidus 1

Interventions

Rituximab 40Cyclophosphamide 36Prednisone 24Doxorubicin 23Magnetic Resonance Spectroscopy 20Vincristine 19Gemcitabine 18Specimen Handling 17Lenalidomide 17Biopsy 15Oxaliplatin 14polatuzumab vedotin 13obinutuzumab 11glofitamab 11ibrutinib 10fludarabine 8Etoposide 8Dexamethasone 8CT-P10 8prednylidene 7deltacortene 7N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 7venetoclax 6tafasitamab 6pembrolizumab 6Prednisolone 6fludarabine phosphate 5acalabrutinib 5R-CHOP protocol 5Immunotherapy, Adoptive 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Spinal Puncture × 90 days × Clear all
NCT03984448 2026-05-29

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
363 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT06784726 2026-05-06

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

University of Washington

Phase 2 Recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
27 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡